Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2023-09-21 Major Shareholding Noti…
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'FORM 8.3 - Dechra Pharmaceuticals plc' and contains the header 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE' under 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is used to disclose insider dealings or significant ownership changes related to a takeover offer, which falls under regulatory requirements concerning director/insider transactions and major shareholdings during M&A activity. While it involves share dealings (like DIRS or POS), the specific context of Rule 8.3 of the Takeover Code strongly aligns with disclosures related to M&A activity (TAR) or insider dealings (DIRS). Since it details the position and dealings of a significant shareholder (Millennium International Management LP) in relation to an offer for Dechra Pharmaceuticals plc, it is most closely related to disclosures required during a takeover/merger scenario. However, the core content is the disclosure of personal/firm share transactions by an interested party, which is the definition of Director's Dealing (DIRS), even if the context is a takeover. Given the options, DIRS covers personal share transactions by executives/directors, and this form reports the position and dealings of a major shareholder/stakeholder during a potential takeover, making it a specialized form of insider/significant holder disclosure. If the focus were purely on the takeover bid itself, TAR would apply, but this is a disclosure *by* an interested party. DIRS is the best fit for reporting personal/firm share transactions by an insider/major holder.
2023-09-21 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly labeled with 'RNS Number : 2376N' and contains the header 'R-1: Standard form for notification of major holdings'. This structure, along with the content detailing changes in voting rights held by Barclays PLC, clearly identifies it as a regulatory filing related to significant share ownership changes, which falls under the category of Major Shareholding Notification (MRQ) based on the content, or potentially a general Regulatory Filing (RNS) if MRQ was not available. However, since 'Major Shareholding Notification' (MRQ) is a specific category provided for changes in significant share ownership levels, it is the most appropriate classification. The document is a direct notification, not an announcement of a report.
2023-09-21 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is a 'Form 8.3' disclosure, which is a standard regulatory filing under the UK Takeover Code. It details the public opening position and dealings in relevant securities by a person with interests representing 1% or more. This type of document is a specific regulatory disclosure required during M&A activity or takeover bids, and it does not fit into the other categories like 10-K, IR, or IP. Since it is a specific regulatory filing required by the Takeover Panel, it is classified as a Regulatory Filing (RNS).
2023-09-20 English
Form 8.3 - Dechra Pharmaceuticals plc - Amendment
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled 'Form 8.3 - Dechra Pharmaceuticals plc - Amendment' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is a Public Opening Position Disclosure/Dealing Disclosure by a person with interests in relevant securities representing 1% or more, typically filed during a takeover or merger situation. This type of filing relates directly to ownership changes and dealings in securities during a takeover bid, which falls under the scope of M&A Activity (TAR) or, more specifically given the context of insider/significant shareholder dealing during a bid, it is a specialized regulatory disclosure. Since the definitions provided do not have a specific code for 'Takeover Code Disclosure' or 'Insider Dealing during a Bid', we must evaluate the closest fit. Director's Dealing (DIRS) covers personal share transactions by directors, but this is a disclosure by a major shareholder (Millennium International Management LP) regarding a specific offer situation. M&A Activity (TAR) covers merger proposals or takeover bids. Given the direct reference to the Takeover Code and the context of an offer (implied by the form type), TAR is the most appropriate category, as it deals with the mechanics surrounding a takeover bid. If TAR were not available, DIRS or RNS would be considered, but TAR captures the context best.
2023-09-20 English
Holding(s) in Company
Director's Dealing Classification · 98% confidence The document is identified by the header 'RNS Number : 1012N' and contains the standard format for 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership (crossing thresholds) by individuals or entities, which falls under regulatory disclosure requirements related to shareholdings. This specific filing reports that Barclays PLC's holdings changed, crossing a threshold, and is dated September 20, 2023. This type of filing is best categorized as a Major Shareholding Notification (MRQ) as it specifically details the resulting situation of voting rights and share ownership changes, which is the core function of an MRQ filing, rather than a general regulatory announcement (RNS).
2023-09-20 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled 'FORM 8.3 - PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is used in the context of a takeover or merger activity to disclose significant holdings and transactions by parties involved. This aligns directly with the definition of M&A Activity (TAR), which covers merger proposals or takeover bids, as this disclosure is a mandatory part of the M&A regulatory framework in the UK (Takeover Code). It is not a general regulatory filing (RNS) because it is highly specific to takeover rules, nor is it a Director's Dealing (DIRS) as it concerns a major investment manager (Millennium International Management LP) in relation to an offer, not just routine insider trading.
2023-09-19 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.